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Abstract  
 Selectins are vascular adhesion molecules that mediate physiological responses such as 
inflammation, immunity and hemostasis. During cancer progression selectins promote various 
steps enabling the interactions between tumor cells and the blood constituents, including 
platelets, endothelial cells, and leukocytes. Selectins are carbohydrate-binding molecules that 
bind to sialylated, fucosylated glycan structures. The increased selectin ligand expression on 
tumor cells correlates with enhanced metastasis and poor prognosis for cancer patients. While, 
many studies focused on the role of selectin as a mediator of tumor cell adhesion and 
extravasation during metastasis, there is evidence for selectins to activate signaling cascade that 
regulates immune responses within a tumor microenvironment. L-selectin binding induces 
activation of leukocytes, which can be further modulated by selectin-mediated interactions with 
platelets and endothelial cells. Selectin ligand on leukocytes, PSGL-1, triggers intracellular 
signaling in leukocytes that are induced through platelet’s P-selectin or endothelial E-selectin 
binding. In this review I summarize the evidence for selectin-induced immune modulation in 
cancer progression that represents a possible target for controlling tumor immunity. 
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Introduction  
 Changes in cell-surface glycosylation is one of the hallmarks of malignant transformation 
and cancer progression (reviewed in Boligan et al. 2015, Hauselmann and Borsig 2014, Pinho 
and Reis 2015). Glycans are oligosaccharides that are covalently bound to the protein either 
through Asn (N-linked glycan) or through Ser or Thr (O-linked glycan) or to lipids. Altered 
cancer glycosylation is characterized by two principal modifications: a) enhanced branching and 
sialylation and; b) incomplete synthesis of glycans (Hauselmann and Borsig 2014, Pinho and 
Reis 2015). Upregulation of glycosyltransferases has been detected virtually in every cancer type 
and is associated with expression of common tumor cell epitopes such sialyl-Lewisx and sialyl-
Lewisa (sLex/sLea), Thomsen-nouvelle antigen (Tn) and sialyl-Tn (sTn) (Fuster and Esko 2005, 
Hauselmann and Borsig 2014, Pinho and Reis 2015).  
Cell-cell recognition, cell adhesion and mobility; and host-pathogen interactions are 
facilitated by lectins in healthy organisms. There is accumulating evidence that glycans also 
modulate immune responses during inflammation, infection and malignancy (Boligan et al. 2015, 
Pearce and Laubli 2016). The ubiquitous expression of lectins on immune cells, endothelial cells 
or as soluble molecules enables them to bind to glycans on tumors cells and thereby regulate 
tumor cell progression. Cancer-associated glycosylation is recognized by the lectin family of 
Siglecs (covered by a separate article in this issue) and Galectins, but there is increasing evidence 
that also selectins and their ligands actively contribute to tumor immunity. 
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Cancer immunity  
Recent progress in cancer immunotherapy showed that stimulation of the immune system can 
lead to anti-tumor response and elimination of tumor cells. The so-called cancer immunity cycle 
describes the steps leading to and effective anti-cancer immune response (Chen and Mellman 
2013). This cycle begins by tumor antigens release, their effective presentation on antigen-
presenting cells, T cell priming, effective T-cell recruitment to tumor sites, recognition of the 
tumor cells and finally their elimination. In addition, cancer progression induces an 
immunosuppressive tumor microenvironment. Selectins were shown to mediate T cell 
recruitment both to the lymph node and to tumor sites, but also myeloid-derived cells to tumors 
(Chen and Mellman 2013, Läubli and Borsig 2010, Ley 2003, Rosen 2004). Thus, selectins 
represent another potential arm to modulate immune responses during cancer progression. 
 
Selectins – vascular cell adhesion molecules 
The selectins are a family of three C-type lectins expressed by bone-marrow-derived cells 
and endothelial cells. These vascular cell adhesion molecules are identified as L-selectin 
expressed on leukocytes, E-selectin expressed on endothelial cells ad P-selectin expressed on 
platelet and endothelial cells. All three selectins have a similar structure consisting of an amino-
terminal lectin domain, one EGF-like domain, several consensus repeats, a single transmembrane 
domains and a carboxy-terminal cytoplasmic domain (Kansas 1996, Ley 2003). The main 
physiological function of all selectins is to mediate leukocyte recruitment to sites of inflammation 
or to lymphoid tissues. Importantly, there is evidence that selectins and selectin ligands also have 
signaling functions (Crockett-Torabi 1998, Läubli and Borsig 2010, Zarbock et al. 2009). P-
5 
 
selectin is found in secretory granules of platelets (α-granules) and endothelial cells (Weibel-
Palade bodies) and upon activation is present on the surface of platelets and endothelial cells. E-
selectin expression on activated endothelial cells requires de novo transcription, thus occurs 
several hours after stimulation and persists for a longer time period as observed in chronic 
inflammation. In addition, E-selectin is expressed in quiescent, non-inflamed, skin microvessels 
and in parts of the bone marrow microvasculature (Keelan et al. 1994, Sipkins et al. 2005). L-
selectin is expressed by all myeloid-derived cells, naïve T cells, and some memory T cells 
(Kansas 1996, Sallusto et al. 1999). In addition, L-selectin has been detected in a non-vascular 
compartment on trophoblasts, mediating the adhesion in the uterus during placental development 
(Prakobphol et al. 2006). 
Selectins mediate interactions among leukocytes, platelets and the endothelial cells in 
various physiological and pathophysiological situations, including inflammation and cancer. All 
selectins have been shown to contribute to metastasis through the recruitment of myeloid-derived 
cells (Borsig et al. 2002, Hauselmann et al. 2016, Läubli et al. 2006). P-selectin-mediated 
platelet-tumor cell interactions promote tumor cell adhesion, L-selectin facilitates myeloid-
derived cells recruitment, and together with E-selectin contribute to efficient tumor cell 
extravasation (reviewed in Läubli and Borsig 2010). The extent of selectin contribution to cancer 
progression is defined by temporal and special presence not only of selectin but also selectin 
ligands.  
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Selectin ligands in cancer 
Selectin ligands are glycan structures that are formed by post-translational modification of 
scaffold proteins by glycosyltransferases (Kansas 1996, Rosen 2004, Varki 1997). The minimal 
recognition motif recognized by all three selectins is a terminal tetrasaccharide sialyl-Lewisx 
(sLex): Siaα2,3-Galβ1,4-(Fucα1,3-)GlcNAc β1-, and its isomer sialyl-Lewisa (sLea): Siaα2,3-
Galβ1,3-(Fucα1,4-)GlcNAcβ1- that are synthesized by α1,3-fucosyltransferases, FucTIV and 
VII; α2,3-sialyltransferases, β1,4-galactosyltransferase GalT-I, and β1-glucosaminyltransferases 
(Kansas 1996, Rosen 2004). Carbohydrates must be presented on specialized protein scaffolds 
that enhance ligand clustering, which enables effective selectin binding (Varki 1997). P-selectin 
glycoprotein ligand- 1 (PSGL-1) is the best characterized selectin ligand for all three selectins. 
For P-selectin high-affinity binding, sulfated tyrosine are required in a close proximity to the 
glycan structure carrying sLex structure. Further modification of the sLex structure by sulfation 
either on galactose or N-acetylglucosamine, 6-sulfo-SLex, increases the L-selectin affinity. 
Natural ligands for L-selectin are presented in the lymph nodes and belong to the family of 
peripheral node addressins (Ley and Kansas 2004, Rosen 2004). In addition, L-selectin binds to 
endothelial heparan sulfate and mediates neutrophil recruitment during inflammation (Wang, L. 
et al. 2005). E-selectin binds to various ligands, including PSGL-1, ESL-1, CD44 and CD34.  
There is compelling clinical and experimental evidence that enhanced expression of sLex 
and sLea correlates with poor prognosis due to enhanced metastasis in a number of tumor types, 
including colon, gastric, prostate, renal, pancreatic and lung cancer (reviewed in Hauselmann and 
Borsig 2014, Kannagi 2004, Kim and Varki 1997). Major carriers of altered glycosylation in 
tumors and particularly carcinomas are mucins. Mucins are large glycoproteins carrying O-
glycans attached to Ser or Thr in tandem repeat sequences. Mucins as carriers of selectin ligands 
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associated with cancer progression are MUC1, MUC2 MUC4 and MUC16 (Hollingsworth and 
Swanson 2004). Also other selectin ligands has been detected during cancer progression on 
properly glycosylated proteins including CD44, CD24, ESL-1, PSGL-1, death receptor-3 and 
podocalyxin-like proteins while this list is still growing (Aigner et al. 1997, Burdick et al. 2006, 
Dimitroff et al. 2005, Gout et al. 2006, Thomas et al. 2009).   
Enhanced selectin ligand expression on tumor cells is clearly associated with cancer 
progression and enables the contact with blood constituents (platelets, leukocytes and the 
endothelium), particularly during metastatic dissemination (Läubli and Borsig 2010, Witz 2008). 
However; recent findings indicate that endogenous selectin ligands on non-malignant cells are 
required for metastasis (Hauselmann et al. 2016, Hoos et al. 2014). Hence, the normal 
physiological selectin function seems to be “hijacked” during cancer progression and represents 
an additional mechanism how selectin modulate to cancer progression.  
 
Selectins shape up the tumor microenvironment 
Selectin-dependent recruitment of leukocytes to tumor sites enhances different steps of 
metastasis including immune invasion, dissemination, extravasation and formation of a metastatic 
niche (Borsig et al. 2002, Hauselmann et al. 2016, Hoos et al. 2014, Ku et al. 2016, Läubli et al. 
2006). The use of selectin-deficient mice in a number of different cancer models have shown that 
selectin-mediated recruitment of myeloid-derived cells (CD11b+Ly6C+Ly6G+) supports tumor 
metastasis (Borsig et al. 2002, Hauselmann et al. 2016, Läubli et al. 2006). Elevated levels of 
selectin ligands by carcinomas are associated with poor prognosis (reviewed in Hauselmann and 
Borsig 2014, Kim and Varki 1997, Pinho and Reis 2015). Selectin-based cell-cell interactions of 
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tumor cells with leukocytes, platelet and endothelial cells have been observed in different animal 
models and appear to be critical for cancer progression (Hauselmann and Borsig 2014, Krause 
and Turner 1999, Pinho and Reis 2015). These findings suggest that selectins support tumor 
progression mainly through the cooption of the inflammatory pathways (Läubli and Borsig 2010). 
Thus, selectins significantly contribute to the formation and maintenance of the tumor 
microenvironment (Figure 1).  
Local activation of the metastatic niche by tumor cells, together with all blood 
components, resulted in enhanced expression of E-selectin and increased production of CCL5 
chemokine (Läubli and Borsig 2009). CCL5 enhanced monocyte recruitment to the site of 
metastatic extravasation, indicating that the selectin-mediated leukocyte recruitment is further 
supported by chemokine-driven mechanisms. This finding is in line with previous observations 
that the neutrophil recruitment was completely blocked only by the combination of E-selectin 
inhibitor and an inhibitor of Gα protein signaling used by most chemokine receptors (Smith et al. 
2004). Tumor-induced endothelial activation during metastasis induces selectin ligand expression 
that contributes to L-selectin dependent recruitment of myeloid-derived cells CD11b+ (Läubli et 
al. 2006). The absence of selectin ligands in non-hematopoietic cells resulted in decreased 
chemokine levels, reduced inflammatory monocytes (Ly6Chi cells), and decreased lung 
metastasis (Hoos et al. 2014). Further investigations showed that an engagement of E-selectin on 
endothelial cells by Ly6Chi cells is essential for loosening of endothelial VE-cadherin-based 
junctions and monocyte-assisted transendothelial migration of tumor cells in the lungs 
(Hauselmann et al. 2016). In addition, activation of extracellular signal-regulated kinase (ERK) 
by E-selectin facilitates the opening of endothelial junctions by Src kinase activation and 
dissociation of VE-cadherin/β-catenin complex (Tremblay et al. 2006). Neutrophil-derived 
9 
 
TNF-α significantly up-regulate selectin ligand expression on non-small cell lung cancer cells (St Hill et al. 2011). As a result, TNF-α stimulation also increased tumor cell adhesion to E-selectin. Taken together, these data support the essential role of selectins in the recruitment 
of innate immune cells during metastatic colonization. 
 
Selectins modulate immune responses 
Selectin-mediated interactions promote leukocyte recruitment to the site of inflammation 
or cancer progression. The involvement of selectin-induced signal transduction in immune 
modulation has just been proposed (Läubli and Borsig 2010, Ley 2003, Rosen 2004, Zarbock et 
al. 2009). There are two major pathways regulating immune responses: a) the engagement of 
PSGL-1 on leukocytes; b) the L-selectin-dependent leukocyte activation.  
PSGL-1   
Selectin binding to PSGL-1 on leukocytes induces activation of several signaling pathways 
(Figure 1C), which is mediated through the cytoplasmic domain of PSGL-1 interacting both with 
cytoskeletal and signaling proteins (reviewed in Zarbock et al. 2009). Deletion of cytoplasmic 
domain of PSGL-1 did not alter leukocyte rolling, but was found to be essential for activation of 
β2 integrins (Miner et al. 2008). The ligation of the extracellular domain of PSGL-1 induces 
downstream signaling through the 69 amino acid long cytoplasmic tail, which interacts with the 
ezrin-radixin-moesin (ERM) protein complex and activate spleen tyrosine kinase (Syk) 
(Urzainqui et al. 2002). Syk is required for integrin activation after E-selectin or P-selectin 
binding to PSGL-1 on neutrophils (Zarbock et al. 2007). In addition, TNF-α triggers neutrophil 
adhesion on E-selectin through CXCR2 expression. Leukocyte-derived CXCL1 actively induces 
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neutrophils arrest, while the inhibition of CXCR2 actively inhibited this process (Zarbock et al. 
2007). The ERM-proteins contain an immunoreceptor tyrosine-like activation motif (ITAM)-like 
domain, which leads to activation of a transcriptional activity (Urzainqui et al. 2002). Mutation of 
the Syk binding site on moesin resulted in reduced transcriptional activity upon ligation of PSGL-
1.  
In other studies, extracellular activation of PSGL-1 has led to tyrosine phosphorylation 
which further activated MAPK and Src kinase signaling pathways in neutrophils (Hidari et al. 
1997, Wang, H. B. et al. 2007). Adhesion of human monocytes to P-selectin enhanced nuclear 
translocation of nuclear factor-kappa B (NF-κB), a transcription factor required for expression of 
CCL2, TNF-α and IL-8 (Weyrich et al. 1995). Blocking of PSGL-1 on monocytes resulted in 
inhibition of cytokine secretion. P-selectin binding to PSGL-1 on leukocytes activates their 
integrins through the Src kinase family, Nef-associated factors 1 and phosphoinositide-3-OH-
kinase (PI3-kinase) signal transduction pathways (Evangelista et al. 2007, Wang, H. B. et al. 
2007).  
Recent studies confirmed the PSGL-1-induced signaling in vivo (Sreeramkumar et al. 
2014, Zuchtriegel et al. 2016). During inflammation, platelets through P-selectin bind to PSGL-1 
on leukocytes that promote the recruitment of neutrophils and inflammatory monocytes to the 
extravasation sites in the venular microvessels (Zuchtriegel et al. 2016). PSGL-1-transduced 
signals resulted in a redistribution of adhesion receptors that drive neutrophil migration 
(Sreeramkumar et al. 2014). In the absence of PSGL-1, neutrophils are unable to polarize their 
adhesion receptors (e.g. integrins) and display aberrant crawling with a subsequent extravasation 
blockade. Specifically, ligation of PSGL-1 by P-selectin induced the high-affinity conformation 
of β2 integrins on the surface of neutrophils and inflammatory monocytes via ERK1/2 MAPK-
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dependent signaling events (Zuchtriegel et al. 2016). The binding of platelets to monocytes via P-
selectin-PSGL-1 interactions was shown to increase expression and activity of α4β1- and αMβ2-
integrins, which increases the binding to the endothelium and transendothelial migration of 
monocytes (da Costa Martins et al. 2006). Importantly, PSGL-1 mediated monocyte activation 
correlated with a concomitant decrease of L-selectin expression. Proteolytic cleavage of L-
selectin is relevant for the physiologic leukocyte rolling, then the inhibition of L-selectin 
shedding significantly decreased the rolling velocity (Hafezi-Moghadam and Ley 1999). 
Blocking of homeostatic L-selectin shedding resulted in an increased recruitment of neutrophils 
to the inflamed tissues, thereby affecting migration patterns in vivo (Venturi et al. 2003). 
L-selectin controls the capacity for naïve T cells to migrate to the lymph nodes (LN), 
whereas P- and E-selectin capture activated T cells on activated inflamed endothelium to initiate 
their migration into non-lymphoid tissues (Hobbs and Nolz 2017). The capacity of T cells to 
interact with vascular selectins is dependent on the enzymatic synthesis of complex O-glycans, 
thus making this cell surface modification indispensable for T cell homing (Ebel et al. 2015). Six 
different cytokines that affect T cell differentiation, including IL-12 IL-18, IL-25 and TGF-β, 
were shown to induce selectin ligand expression above the levels induced by TCR engagement. 
The selectin ligand expression was blocked by inhibition of p38 MAPK, which has been 
identified to be required for Fut7 and CgNt1 expression, both enzymes critical for production of 
sLex (Ebel et al. 2015). This highly flexible O-glycan synthesis in T cells is in contrast to myeloid 
cells with minimal changes in glycosylation (Hobbs and Nolz 2017) and represents yet another 
level of selectin-dependent leukocyte activation in T-cells.    
PSGL-1 has several functions beyond mediating selectin-dependent leukocyte 
recruitment, including modulation of T cells and interactions with CCL19 and CCL21 
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chemokines (Tinoco et al. 2016, Veerman et al. 2007). T cell entry to secondary lymphoid organs 
is promoted by PSGL-1 interaction with CCL19 and CCL21. The recent evidence shows that 
PSGL-1 is a check-point regulator of T cells where PSGL-1 engagement leads to T-cell 
exhaustion (Tinoco et al. 2016). Ligation of PSGL-1 on CD8+ cells inhibited IL-2 and T cell 
receptor signaling and upregulated programmed cell death expression protein 1 (PD-1). PSGL-1 
deficiency in a melanoma model led to improved T cell responses and tumor control due to 
downregulation of PD-1 (Tinoco et al. 2016). Tumor infiltrating effector CD8+ and CD4+ T cells 
were significantly increased in PSGL-1-deficient mice. Interestingly, neither selectin blockade 
nor deficiency in CCL19 and CCL21 alter CD8+ T cell numbers or PD-1 expression, thus the 
immune regulation through PSGL-1 is mediated by a presently unknown ligand.   
 
L-selectin 
Initial observations that antibody-based cross-linking of L-selectin on neutrophils primed 
these cells and induced an up-regulation of cell surface expression of Mac-1 epitope, a αMβ2 
integrin (Crockett-Torabi et al. 1995) provided the first evidence that L-selectin activation may 
induce intracellular signaling cascade. Another study demonstrated that L-selectin cross-linking 
increased L-selectin adhesion and transmigration efficiency of neutrophil through endothelial 
cells (Simon et al. 1995). Further analysis of neutrophils revealed that L-selectin activation 
increased intracellular calcium levels in a dose dependent manner (Crockett-Torabi et al. 1995, 
Laudanna et al. 1994, Waddell et al. 1994) and led to respiratory burst and O2- generation 
(Crockett-Torabi et al. 1995, Waddell et al. 1994). Induced expression of TNF-α and IL-8 
cytokines was observed in L-selectin-activated neutrophils with a sulfatide; 3-O-
sulfogalactosylceramide (Laudanna et al. 1994). Finally, L-selectin clustering on the cell surface 
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of neutrophils activates p38 mitogen-activated protein kinase to induce shape change, integrin 
activation and release of secretory granules (Smolen et al. 2000). Further study showed that L-
selectin triggering on human T cell line, Jurkat cells, stimulated Ras pathway that required 
presence of a functional tyrosin kinase p56 (Brenner et al. 1996). Phosphorylation of the 
cytoplasmic tail of L-selectin leads to a release of calmodulin that occurs during shedding of the 
L-selectin (Kahn et al. 1998). Taken together, these in vitro studies have shown that L-selectin 
triggers functional responses (Crockett-Torabi 1998, Ivetic 2013), however; L-selectin activation 
in these studies was not triggered by selectin ligands.  
The biological relevance of L-selectin endoproteolytic cleavage has been studies in 
transgenic mice, with mutation in the cleavage site that was blocking L-selectin shedding or using 
defective in tumor necrosis factor α-converting enzyme (ADAM 17) deficient mice (Venturi et al. 
2003, Walcheck et al. 2003). Although upon stimulation L-selectin shedding occurred also in 
ADAM-17-deficient leukocytes, the ADAM-17 reconstitution significantly increased the 
turnover of L-selectin (Walcheck et al. 2003). Blocking the cleavage of T cells on antigen-
stimulated T cells resulted in their accumulation in the LN, while activation in wild type cells 
showed a significant decrease in L-selectin (Venturi et al. 2003). L-selectin cleavage regulates 
activation-induced changes in L-selectin density. Neutrophils in cleavage-resistant mice centered 
the inflamed peritoneum in greater numbers and for longer period that wt neutrophils, which shed 
off L-selectin rapidly upon migration (Venturi et al. 2003). Rapid metalloproteinase-dependent 
shedding of L-selectin occurred upon TCR engagement on antigen-activated T cells (Galkina et 
al. 2003). While shedding-resistant cells continued to migrate to LNs, L-selectin shedding from 
antigen-activated T cells prevented reentry to LNs. Thus, L-selectin shedding controls the 
capacity of activated T cells to migrate to peripheral LNs (Galkina et al. 2003, Venturi et al. 
14 
 
2003). L-selectin shedding is directly linked to trans-endothelial migration of monocytes, since 
L-selectin is effectively removed from the transmigrating pseudopods of migrating cells 
(Rzeniewicz et al. 2015). Calmodulin/L-selectin interaction, which acts to block shedding, is lost 
through Ser phosphorylation of the L-selectin cytoplasmic tail, occurring specifically within 
transmigrating pseudopods. Hence, L-selectin shedding directly regulates polarity in 
transmigrated monocytes through activated endothelial cells (Rzeniewicz et al. 2015). L-selectin 
expression is reduced in lymphatic cells, upon arrival to the LNs, but CD8+ T-cells re-express L-
selectin upon reentering the circulation and the recruitment of CD8+ cells to infected tissues is L-
selectin dependent (Mohammed et al. 2016). Importantly, L-selectin expression of T cells confers 
protective immunity. 
The current evidence for the L-selectin involvement in immune modulation is mostly 
based on various inflammatory and infectious models. While many parallels between 
inflammation and cancer progression has been described, it remains to be tested to which extent 
selectin-mediated modulation of immune responses contribute to cancer progression.  
 
L-selectin modulate adaptive and innate immunity in cancer 
The capacity of leukocyte to either promote or control cancer progression largely depends 
on spatial and temporal stimulation of the tumor microenvironment (Coussens and Werb 2002, 
Mantovani et al. 2008). This modulation of cancer progression depends on the recruitment of 
leukocytes and their activation status. While several adhesion mechanisms have been implicated 
in leukocyte recruitment (e.g. chemokine, integrins, and cell-surface ligand presentation), 
selectin-mediated recruitment has been observed in many preclinical models. L-selectin-mediated 
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leukocyte recruitment to tumor or to metastatic sites represents one possible mechanism that has 
been explored mostly using L-selectin deficient mice. Several studies have shown that L-selectin 
dependent monocytes recruitment promoted lung metastasis through enhancement of tumor cell 
extravasation (Borsig et al. 2002, Hoos et al. 2012, Läubli et al. 2006). Recently, the use of 
spontaneous metastatic model resulted in reduced lung metastasis, but an increase in metastasis to 
other organs (L.B. manuscript in preparation). The apparent tissue-dependent differences in 
modulation of cancer progression through L-selectin have been linked to recruitment of distinct 
leukocyte subpopulation.  
Myeloid-derived suppressor cells (MDSCs) accumulate in most cancer patients and also 
in experimental animals with cancer. MDSCs suppress both innate and adaptive antitumor 
immunity by various mechanisms including sequestration of cysteine and down-regulation of L-
selectin (Ostrand-Rosenberg 2010). Antigen-naïve T cells upon encounter of antigens become 
activated and are directed to the LN in an L-selectin-dependent manner. During cancer, MDSCs 
actively suppress L-selectin presence on T cells as has been shown by co-culture of CD4+ and 
CD8+ cells with MDSCs (Hanson et al. 2009). In a mouse model surgical removal of a tumor is 
associated with a reduction of MDSC levels and an increased expression of L-selectin on 
circulating T cells. Initial investigations suggested that L-selectin shedding is dependent on 
surface expression of ADAM17 on MDSCs (Hanson et al. 2009, Ostrand-Rosenberg 2010). The 
use of ADAM17-deficient mice showed reduced L-selectin levels in tumor-bearing nice when 
compared to naïve animals, thus providing evidence that down-regulation of L-selectin on T and 
B cells occurs also in a ADAM17 independent manner (Ku et al. 2016). Importantly, the loss of 
L-selectin on T cells occurs within the MDSC-enriched blood compartment and in a contact-
dependent manner, although the exact mechanism remains unclear. Even moderate reduction in 
L-selectin expression impaired T-cell trafficking to peripheral LNs (Ku et al. 2016). 
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Consequently, T cells preconditioned with MDSCs have diminished responses to subsequent 
antigen exposure, thereby severely restricting antigen-driven cell expansion in the LNs.  
The regulation of L-selectin expression is essential for controlling the traffic of T 
lymphocytes to and from the peripheral LNs. To evaluate the relationship between L-selectin 
shedding and T cell activation, an in vitro anti-tumor antigen generated T cells were assessed 
with a panel of melanoma cells (Yang et al. 2011). In the human system, the encounter of T cell 
with tumor cells has led to a rapid decrease of L-selectin from the cell surface, which correlated 
with an increased expression of a lysosomal-associated membrane protein-1 (CD107a). CD107a 
serves as a marker of T-cell degranulation and release of granzyme B and perforin, reflecting the 
lytic potential of these cells. This observation suggests that antigen-dependent T cell stimulation 
leads to L-selectin shedding. In another study, ex vivo cultured murine lymphocytes used for 
adoptive immunotherapy to treat B16 melanoma in mice showed that early effector T cells 
controlled much better the melanoma growth than more differentiated effector T cells with 
enhanced in vitro antitumor properties (Gattinoni et al. 2005). There was a strong difference in L-
selectin expression, which was significantly reduced in more differentiated, but less potent CD8 
T cells in vivo. While the immune system balances T cell homing and effector function of T cells, 
these data suggest that L-selectin is involved in acquisition of an effector function, although the 
exact mechanism remains to be defined.  
In hematogenous malignancies, tumor cells not only express selectin ligands, but also 
express L-selectin itself. L-selectin on the surface of leukemia cells can affect their trafficking 
and distribution. In patients with chronic lymphocytic leukemia (CLL), tumor cells are re-
circulating to LN through L-selectin mediated rolling, which promotes cancer progression 
(Lafouresse et al. 2015). Interestingly, a clinically approved inhibitor for treatment of CLL, a 
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PI3-kinase delta inhibitor, Idelalisib, decreased L-selectin expression. This might be one possible 
mechanism how this drug is interfering with CLL progression (Lafouresse et al. 2015). However, 
L-selectin expression on B-cell lymphoma cell line was not associated with LN metastasis 
(Aviram et al. 2001). Further studies will be required to assess the involvement of L-selectin in 
hematogenous malignancies.  
 The newly described mechanism of adoptive immunity modulation through MDSCs that 
is dependent on down regulation of L-selectin has further implications for systemic cancer 
immunity. Since virtually all leukocyte population express L-selectin, the involvement of L-
selectin in regulation of innate and adoptive immune cells guarantees further investigations. 
 
Conclusions and outlook 
Selectins expressed on leukocytes, platelets and endothelial cells are among the first 
adhesion molecules that induce intracelullar signaling once binding to selectin ligands. The 
virtual omnipresence of selectin ligands on tumor cells is linked to cancer-associated aberrant 
glycosylation (Boligan et al. 2015, Hauselmann and Borsig 2014, Pinho and Reis 2015) and 
makes selectins potential targets for cancer therapy. In addition, other lectin binding molecules, 
such as Siglecs, have been described to modulate immune responses during cancer and are 
covered in this issue (Läubli and von Gunten article in this issue). Cancer immunotherapy, 
particularly focusing on PD-1 and CTLA-4 pathways, is actively being pursued also in the 
clinical settings (reviewed in Boussiotis 2016, Burugu et al. 2017). However; the potential to 
target tumor glycans-induced interactions, e.g. through selectins, has not be explored. Yet, 
several studies describe mechanisms how selectins modulate immune responses that have the 
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potential to be therapeutically targeted (Dinkla et al. 2016, Shamay et al. 2016, Tian et al. 2016). 
Differentiation of regulatory T cells (Treg) into IL-17 producing cells was inhibited by presence 
of platelet microparticles (Dinkla et al. 2016). This inhibition of Treg plasticity was dependent on 
P-selectin binding to PSGL-1 specifically on memory-like Treg cells. Blocking of P-selectin 
restored Treg differentiation and L-selectin expression. In addition, platelets microparticles 
further modulated Treg differentiation through platelet-derived CXCL4 binding to CXCR3 on 
leukocytes (Dinkla et al. 2016). Natural killer cells expressing L-selectin has been linked to 
persistence of these cells in tumors, where they control tumor progression (Tian et al. 2016). 
Thus, an enrichment of natural killer T cells expressing L-selectin is a target for an efficient 
cancer immunotherapy. Finally, P-selectin ligands have been used for specific targeting of MEK 
kinase inhibitor to metastatic tumors that resulted in tumor cell apoptosis (Shamay et al. 2016). 
Interestingly, tumors are specifically targeted by fucosylated polysaccharide coated nanoparticles 
carrying the inhibitor through an ionizing radiation that induces the local endothelial activation, 
associated with P-selectin expression.  
Selectin has been studied in a number of pathological situations, e.g. ischemia-reperfusion 
injury, inflammation etc. (Ivetic 2013, Ley 2003, McEver 2015), providing the rationale for 
development of selectin inhibitors. Abundant experimental evidence suggests that selectin 
targeting inhibits metastasis (Barthel et al. 2007, Läubli and Borsig 2010, St Hill 2011). To which 
extent the observed inhibition of metastasis is mediated by alteration of immune responses 
through selectin remains to be further evaluated. Interestingly, the treatment of cancer patients 
with heparin, as an anticoagulant, inadvertently inhibited also P- and L-selectins (Borsig et al. 
2007). The inherited tumor heterogeneity includes also the composition of differentially activated 
immune cells represents the major challenge for development of an approach to modulate 
immune responses. Since altered cancer glycosylation is a common culprit in tumors, the 
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understanding of lectin-mediated mechanisms involved in immune responses, including selectins 
and Siglecs, represents another strategy to target cancer progression.  
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Figure legends 
Figure 1. Selectin-dependent signaling during cancer progression. A) Primary tumor sites: 
Tumor cells produce various cytokines leading to endothelial activation that result in a leaky 
vasculature. Tumor-derived chemokines facilitate leukocyte recruitment and their extravasation. 
Leukocytes expressing PSGL-1 infiltrate tumors through binding to vascular selectins (P- and E-
selectin). Platelets further promote leukocyte adhesion through P-selectin-mediated interactions. 
B) Metastatic sites: Selectins promote tumor cell-endothelial interaction and the recruitment of 
leukocytes. a: Platelet binding to tumor cells and to the endothelium promote tumor cell 
adhesion; b: Platelet-tumor cell interactions are largely facilitated by P-selectin; c: Selectin-
triggered endothelial activation leads to leukocyte-assisted tumor cell extravasation. C) The 
intracellular signaling in leukocytes is initiated through selectin-binding to PSGL-1 on leukocytes 
resulting in 1: activation of MAPK and src kinase pathways; 2: activation of integrins; 3: 
activation of NF-κB pathways and secretion of cytokines (e.g. CCL2, IL-8 or TNF-α; 4: 
shedding of cell surface L-selectin.  
 
Figure 2. L-selectin-triggered intracellular signaling in leukocytes. L-selectin binding to 
ligands causes selectin clustering, which induces receptor tyrosine and serine phosphorylation 
and activation of the ERM proteins. This leukocyte activation further results in: 1 integrin 
activation through MAPK kinase; 2 leukocyte degranulation, particularly by neutrophils; 3 
activation of the ras pathway; 4 L-selectin shedding, which modulates immune responsiveness of 
leukocytes.   
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